FindTrial
Sign In

The double blind randomized comparative study of MRQ-01 in the cancer patients with breakthrough pain.

The double blind randomized comparative study of MRQ-01 in the cancer patients with breakthrough pain.

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080222864
Enrollment
84
Registered
2015-05-26
Start date
2015-05-26
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer-related breakthrough pain

Interventions

investigational material(s) Generic name etc : MRQ-01 INN of investigational material : fentanyl Therapeutic category code : 821 Synthetic narcotics Dosage and Administration for Investigational mater

Sponsors

Maruishi Pharmaceutical Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: The cancer-related breakthrough pain which rescue needs

Exclusion criteria

Exclusion criteria:

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026